Genmab — August 2018

[dohk]

DGAP-News: MorphoSys and I-Mab Biopharma Announce China IND Submission of TJ202/MOR202

NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune diseases, announced today that I-Mab has submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma. Multiple myeloma is the second most common blood cancer worldwide. The patient number has gradually increased in China in recent years due to an increasingly aging population.

Yahoo Finance (finance.yahoo.com)

[bibob]

Det kunne jo være at kineserne fik øjnene op for Dara , da det jo er succesfuldt mod cd38. Hvorfor så vente på noget ringere.

[Tandfeen-2]

Kan jeg stille spørgsmål til Q & A her: What is the status for the subcutan version of Darzalex? And what is the status for darzalex in rheumatological diseases?

[Helge_LarsenPI-redaktør]

Hvorfor ikke direkte i Q&A chatten lige nu?

[Helge_LarsenPI-redaktør]

Du melder dig til her. http://www.proinvestor.com/index.php?p=q-and-a&groupid=92

[Helge_LarsenPI-redaktør]

Derefter kan du stille spørgsmålet i Q&A chatten. Den finder du i drop down boxen.

[Tandfeen-2]

Jeg prøver der

[Helge_LarsenPI-redaktør]

Tak Tandfe...Spørgsmålet er gået ind.

[E_L]

http://globenewswire.com/news-release/2018/08/08/1548832/0/en/Genmab-Announces-Submission-of-U-S-EU-Regulatory-Applications-Seeking-Approval-of-DARZALEX-Daratumumab-Split-Dosing-Regimen.html

[E_L]

Genmab Announces Submission of U.S. & EU Regulatory Applications Seeking Approval of DARZALEX (Daratumumab) Split Dosing Regimen

[E_L]

nice timing

[Tandfeen-2]

Får det nogen betydning?

[Peter_Panik]

Nordea atter største nettosælger

[kkjoel]

Helge, fik du mit spørgsmål i Q&A chatten?

[kkjoel]

Nordnets nyhedstelegram om split dosing https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=490848013&sourcecode=ddk

[henrik48]

Kursen lader til at forberede sig på et hop op ad efter regnskab

[JKY_VH]

Det kan vi da håbe Henrik

[Helge_LarsenPI-redaktør]

kkjoel..Det gjorde jeg. Kan ikke redigere i det.

[gentogen]

Fra tidligere forsøg:"Conclusions: Additional prophylaxis for IRRs and a modified split dose regimen may reduce the risk of IRR with dara and provide for safe outpatient administration with an 8-hour clinic schedule."

[gentogen]

In our experience, IRRs were significantly reduced when compared to the FDA registry trials. Knowledge of improved tolerance to therapy and easier administration may increase use of daratumumab in the community.